ENTRY       D10627                      Drug
NAME        Esketamine hydrochloride (JAN/USAN);
            Spravato (TN)
PRODUCT     SPRAVATO (Janssen Pharmaceuticals)
FORMULA     C13H16ClNO. HCl
EXACT_MASS  273.0687
MOL_WEIGHT  274.1862
CLASS       Neuropsychiatric agent
             DG01498  NMDA receptor antagonist
            Metabolizing enzyme substrate
             DG02919  CYP2B6 substrate
             DG01642  CYP2C9 substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
REMARK      ATC code: N01AX14 N06AX27
            Chemical structure group: DG01829
            Product (DG01829): D10627<US>
EFFICACY    Antidepressant, NMDA receptor antagonist
COMMENT     Treatment of depression
TARGET      GRIN (NMDAR) [HSA:2902 2903 2904 2905 2906] [KO:K05208 K05209 K05210 K05211 K05212]
  PATHWAY   hsa04080(2902+2903+2904+2905+2906)  Neuroactive ligand-receptor interaction
            hsa04724(2902+2903+2904+2905+2906)  Glutamatergic synapse
METABOLISM  Enzyme: CYP2B6 [HSA:1555], CYP3A4 [HSA:1576]; CYP2C9 [HSA:1559], CYP2C19 [HSA:1557], UGT [KO:K00699]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N01 ANESTHETICS
               N01A ANESTHETICS, GENERAL
                N01AX Other general anesthetics
                 N01AX14 Esketamine
                  D10627  Esketamine hydrochloride (JAN/USAN) &lt;US&gt;
              N06 PSYCHOANALEPTICS
               N06A ANTIDEPRESSANTS
                N06AX Other antidepressants
                 N06AX27 Esketamine
                  D10627  Esketamine hydrochloride (JAN/USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antidepressants
              Antidepressants, Other
               Esketamine
                D10627  Esketamine hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01498  NMDA receptor antagonist
               DG01829  Esketamine
                D10627  Esketamine hydrochloride
             Metabolizing enzyme substrate
              DG02919  CYP2B6 substrate
               DG01829  Esketamine
                D10627  Esketamine hydrochloride
              DG01642  CYP2C9 substrate
               DG01829  Esketamine
                D10627  Esketamine hydrochloride
              DG01639  CYP2C19 substrate
               DG01829  Esketamine
                D10627  Esketamine hydrochloride
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01829  Esketamine
                 D10627  Esketamine hydrochloride
              DG02924  UGT substrate
               DG01829  Esketamine
                D10627  Esketamine hydrochloride
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Ligand-gated ion channels
               Glutamate (ionotropic), NMDA
                GRIN (NMDAR)
                 D10627  Esketamine hydrochloride (JAN/USAN) &lt;US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10627
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10627
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01498  NMDA receptor antagonist
               DG01829  Esketamine
             Metabolizing enzyme substrate
              DG02919  CYP2B6 substrate
               DG01829  Esketamine
              DG01642  CYP2C9 substrate
               DG01829  Esketamine
              DG01639  CYP2C19 substrate
               DG01829  Esketamine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01829  Esketamine
              DG02924  UGT substrate
               DG01829  Esketamine
DBLINKS     CAS: 33643-47-9
            PubChem: 254741588
ATOM        17
            1   C1z C    18.4150  -16.0505
            2   C8y C    17.2286  -16.7484
            3   C5x C    19.8108  -16.0505
            4   C1x C    17.7171  -14.8640
            5   N1b N    19.1129  -17.2369
            6   C8y C    15.9723  -16.0505
            7   C8x C    17.2286  -18.1442
            8   C1x C    20.5088  -14.7942
            9   O5x O    20.5088  -17.2369
            10  C1x C    18.4150  -13.6078
            11  C1a C    18.4150  -18.4932
            12  C8x C    14.7859  -16.7484
            13  X   Cl   15.9723  -14.6547
            14  C8x C    15.9723  -18.8421
            15  C1x C    19.8108  -13.6078
            16  C8x C    14.7859  -18.1442
            17  X   Cl   22.5337  -16.6801
BOND        17
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     1   5 1 #Down
            5     2   6 2
            6     2   7 1
            7     3   8 1
            8     3   9 2
            9     4  10 1
            10    5  11 1
            11    6  12 1
            12    6  13 1
            13    7  14 2
            14    8  15 1
            15   12  16 2
            16   10  15 1
            17   14  16 1
///
